Arbor Biotechnologies is a series c plus startup. 2 investors tracked.
Arbor Biotechnologies is a startup founded in 2018 based in the United States. Its most recent tracked round is Series-c-plus. Brouky records 2 investors associated with the company.
Arbor Biotechnologies is a clinical-stage biotechnology company focused on discovering and developing next-generation gene editing therapeutics for genetic diseases affecting the liver and central nervous system.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.